Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/139372METHOD FOR PREPARING AGENT FOR PREVENTION OF HAIR LOSS AND PROMOTION OF HAIR REGROWTH THROUGH FUSION FERMENTATION OF LACTIC ACID BACTERIA
WO 30.06.2022
Int.Class A61K 35/744
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Appl.No PCT/KR2021/019416 Applicant KUNYOUNG ENC. CO., LTD. Inventor LEE, Chae Kun
The present invention is characterized by implementation of a method for preparing an agent for prevention of hair loss and promotion of hair regrowth wherein aerobic lactic acid bacteria and anaerobic lactic acid bacteria are fermented in a fusion manner to repeat a cycle of fermentation, degradation, and synthesis whereby the prevention of hair loss and the promotion of hair regrowth are achieved through the fused fermentation process of lactic acid bacteria.
2.WO/2022/139537POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF
WO 30.06.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/KR2021/019790 Applicant LG CHEM, LTD. Inventor LEE, Ji Hyun
The present invention relates to a polypeptide binding to mucin 1, an isolated polynucleotide encoding same, a vector carrying the polynucleotide, and a cell including the vector. In addition, the present invention relates to a chimeric antigen receptor including the polypeptide binding to mucin 1, an isolated polynucleotide encoding the chimeric antigen receptor, a vector carrying the polynucleotide, an immune cell expressing the chimeric antigen receptor, a composition comprising same for treatment of cancer, and a method for treatment of cancer.
3.WO/2022/136057USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO 30.06.2022
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/EP2021/085935 Applicant PROBIOGEN AG Inventor BAKACS, Tibor
The present invention relates to a birnavirus for use in the treatment or prevention of cancer. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment or prevention of cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment or prevention of cancer.
4.WO/2022/140587COMPOSITIONS AND METHODS FOR GENETICALLY MODIFYING CIITA IN A CELL
WO 30.06.2022
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No PCT/US2021/064933 Applicant INTELLIA THERAPEUTICS, INC. Inventor HARRINGTON, William Frederick
Compositions and methods for reducing MHC class II protein expression in a cell comprising genetically modifying CIITA for use e.g., in adoptive cell transfer therapies.
5.20220202877COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS
US 30.06.2022
Int.Class A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
Appl.No 17646140 Applicant MD HEALTHCARE INC. Inventor Yoon-Keun KIM

Provided is a method for preventing, alleviating or treating an ocular disease including administering a composition containing vesicles derived from Micrococcus luteus as an active ingredient wherein the vesicles are delivered to the central nervous system including the retina through the blood-brain barrier (BBB); when epithelial cells and macrophages were treated with the vesicles, not only is the secretion of an inflammatory mediator by a biological causative factor considerably inhibited, but also NLRP3 protein expression by a biological causative factor is inhibited; and when the vesicles are administered to a rabbit model with an ocular disease caused by oxidative stress, retinal degeneration is significantly inhibited, thus the vesicles derived from Micrococcus luteus can be used for a composition for preventing, alleviating or treating an age-related ocular disease and an inflammatory ocular disease, including a pharmaceutical or health functional food composition.

6.WO/2022/136551REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES
WO 30.06.2022
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/EP2021/087306 Applicant CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN Inventor KATH, Jonas Christian
The invention relates to a nucleic acid construct for targeting and integrating a CD3 zeta-deficient chimeric antigen receptor (CAR) fragment into an endogenous CD3 zeta/CD247 gene of a host genome. The invention further relates to a genetically modified human cell expressing an exogenous nucleic acid sequence encoding a CD3 zeta deficient CAR fragment, integrated in- frame into the endogenous CD3 zeta/CD247 gene for gene fusion, to form a functional CAR comprising an exogenous CAR fragment fused with an endogenous CD3 zeta domain.
7.WO/2022/134031CHEMICAL INDUCTION METHOD FOR PHOTORECEPTOR NEURON CELLS
WO 30.06.2022
Int.Class C12N 5/071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
Appl.No PCT/CN2020/139521 Applicant IREGENE THERAPEUTICS LTD Inventor WEI, Jun
Provided is a pure chemical induction method for photoreceptor neuron cells. A group of small molecule inhibitors are added into a serum-free basic culture medium, and pluripotent stem cells are quickly converted into photoreceptor neuron cells. In the present invention, serum is not used, and chemical small molecules are used to replace retinol, eliminating the adverse factors of serum while ensuring the operation of visual circulation required by the development of photoreceptor neurons.
8.WO/2022/140361GENETICALLY ENGINEERED LYMPHOCYTES FOR ADOPTIVE CELL THERAPY
WO 30.06.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2021/064574 Applicant LUDWIG INSTITUTE FOR CANCER RESEARCH LTD Inventor COUKOS, George
Provided herein are lymphocytes suitable for use in adoptive cell transfer or adoptive cell therapy, as well as methods of making such lymphocytes and methods of using such lymphocytes in the treatment or cancer. Disclosed herein are lymphocytes that are genetically modified to express a glucose transporter and that are in contact with one or more cytokines. Also disclosed herein are lymphocytes that are genetically modified to express an amino acid transporter and an aminoacyl-tRNA synthetase.
9.WO/2022/137181CO-USE OF LENALIDOMIDE WITH CAR-T CELLS
WO 30.06.2022
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No PCT/IB2021/062216 Applicant CRISPR THERAPEUTICS AG Inventor DAR, Henia
A method for producing T cells expressing a chimeric antigen receptor (CAR-T cells), comprising: (i) culturing CAR-T cells in a medium comprising lenalidomide or a derivative thereof to produce CAR-T cells, and optionally (ii) administering the CAR-T cells to a subject in need of the treatment.
10.20220202872METHOD FOR GENERATING A THREE-DIMENSIONAL NEUROMUSCULAR ORGANOID IN VITRO
US 30.06.2022
Int.Class A61K 35/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
Appl.No 17372160 Applicant MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT Inventor Asimina GKOUTI

A method for generating a three-dimensional neuromuscular organoid in vitro is disclosed. This method comprises the following steps: a) providing a first cell culture comprising neuromesodermal progenitor cells and cultivating the neuromesodermal progenitor cells in a first differentiation medium chosen from the group consisting of i) a non-supplemented serum-free cell culture medium and ii) a serum-free cell culture medium supplemented with at least one of a ROCK inhibitor, an activator of a growth factor signaling pathway, and an activator of an insulin signaling pathway; b) replacing the first differentiation medium by a second differentiation medium within 1 to 3 days after cultivation start, wherein the second differentiation medium is chosen from the group consisting of i) a non-supplemented serum-free cell culture medium and ii) a serum-free cell culture medium supplemented with at least one of an activator of a growth factor signaling pathway, and an activator of an insulin signaling pathway; c) replacing the second differentiation medium by a non-supplemented serum-free cell culture medium within 1 to 3 days after replacing the first differentiation medium by the second differentiation medium; and d) obtaining a three-dimensional neuromuscular organoid from the non-supplemented serum-free cell culture medium.